Radioactive microdose reveals Drug's journey in healthy men
NCT ID NCT07578636
First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 6 times
Summary
This Pfizer study in 9 healthy men uses a tiny amount of radioactive carbon to track how the experimental drug PF-07799544 is absorbed, distributed, and eliminated from the body. Participants receive the drug by mouth and by IV, and samples of blood, urine, and stool are collected. The goal is purely to understand the drug's behavior, not to treat any condition.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- PF-07799544 (with a radioactive carbon tracer)
- What this could lead to
- If successful, this study will help researchers understand how PF-07799544 is absorbed and removed from the body, which can guide future dosing and development.
- What could go wrong
- This is a very early Phase 1 study with only 9 healthy men. It is designed to gather information, not to treat any disease. The radioactive tracer is safe at these low levels, but the drug itself may have unknown side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
9 people
The number who actually took part.
- Started
-
May 2026
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Males 18 to 55years of age, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead ECGs. BMI of 17.5-32 kg/m2; and a total body weight \>50 kg (110 lb). Exclusion Criteria: Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing. Previous administration of an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study. Total 14C radioactivity measured in plasma should not exceed 2.5 × standard biological carbon ratio.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy male volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit Inc.
Madison, Wisconsin, 53704, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.